Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye.
Tekinalp A, Gedük A, Akdeniz A, Terzi Demirsoy E, Gürsoy V, Aslaner Ak M, Bağcı M, Seçilmiş S, Keklik Karadağ F, Oruç Uysal A, Doğan A, Demircioğlu S, Erol HA, Aslan C, Özkalemkaş F, Ertop Ş, Dağlı M, Dal MS, Saydam G, Merter M, Ural C, Çeneli Ö. Tekinalp A, et al. Among authors: geduk a. Turk J Haematol. 2023 Dec 5;40(4):242-250. doi: 10.4274/tjh.galenos.2023.2023.0029. Epub 2023 Nov 14. Turk J Haematol. 2023. PMID: 37961952 Free PMC article.
Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.
Aslaner Ak M, Gedük A, Acar İH, Polat MG, Sunu C, Bolaman AZ, Hacıbekiroğlu T, Güvenç B, Ertop Ş. Aslaner Ak M, et al. Among authors: geduk a. Turk J Haematol. 2023 May 29;40(2):92-100. doi: 10.4274/tjh.galenos.2023.2022.0437. Epub 2023 Feb 17. Turk J Haematol. 2023. PMID: 36799095 Free PMC article.
Effects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma.
Geduk A, Oztas B, Eryılmaz BH, Demirsoy ET, Menguc MU, Unal S, Mersin S, Polat MG, Aygun K, Yenihayat EM, Albayrak H, Erol HA, Balcı S, Mehtap O, Tarkun P, Hacihanefioglu A. Geduk A, et al. Indian J Hematol Blood Transfus. 2023 Apr;39(2):220-227. doi: 10.1007/s12288-022-01574-6. Epub 2022 Oct 17. Indian J Hematol Blood Transfus. 2023. PMID: 37006982 Free PMC article.
A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A, Ozkalemkas F, Dogu MH, Tekinalp A, Alacacioglu I, Guney T, Ince I, Geduk A, Cagliyan GA, Maral S, Serin I, Gunduz E, Karakus V, Bekoz HS, Eren R, Pinar IE, Gunes AK, Sargın FD, Sevindik OG. Gemici A, et al. Among authors: geduk a. Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):e686-e692. doi: 10.1016/j.clml.2021.04.004. Epub 2021 Apr 20. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34059487
The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study.
Ak MA, Sahip B, Geduk A, Ucar MA, Kale H, Hacibekiroglu T, Polat MG, Kalpakci Y, Bolaman AZ, Guvenc B, Ertop S. Ak MA, et al. Among authors: geduk a. Indian J Hematol Blood Transfus. 2022 Apr;38(2):299-308. doi: 10.1007/s12288-021-01458-1. Epub 2021 Jun 26. Indian J Hematol Blood Transfus. 2022. PMID: 35496974 Free PMC article.
Correction to: Efects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma.
Geduk A, Oztas B, Eryılmaz BH, Demirsoy ET, Menguc MU, Unal S, Mersin S, Polat MG, Aygun K, Yenihayat EM, Albayrak H, Erol HA, Balcı S, Mehtap O, Tarkun P, Hacihanefioglu A. Geduk A, et al. Indian J Hematol Blood Transfus. 2023 Jul;39(3):518. doi: 10.1007/s12288-023-01626-5. Epub 2023 Jan 18. Indian J Hematol Blood Transfus. 2023. PMID: 37304480 Free article.
28 results